Chimerix Inc. (NASDAQ:CMRX) went up by 6.09% from its latest closing price compared to the recent 1-year high of $11.57. The company’s stock price has collected 7.99% of gains in the last five trading sessions. Press Release reported on 06/04/21 that Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA(R) (brincidofovir) for the Treatment of Smallpox
Is It Worth Investing in Chimerix Inc. (NASDAQ :CMRX) Right Now?
Plus, the 36-month beta value for CMRX is at 1.57. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for Chimerix Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $17.83. CMRX currently public float of 75.55M and currently shorts hold a 4.48% ratio of that float. Today, the average trading volume of CMRX was 739.54K shares.
CMRX’s Market Performance
CMRX stocks went up by 7.99% for the week, with a monthly drop of -4.39% and a quarterly performance of -4.97%, while its annual performance rate touched 113.04%. The volatility ratio for the week stands at 5.36% while the volatility levels for the past 30 days are set at 5.62% for Chimerix Inc.. The simple moving average for the period of the last 20 days is 1.64% for CMRX stocks with a simple moving average of 10.99% for the last 200 days.
Analysts’ Opinion of CMRX
Many brokerage firms have already submitted their reports for CMRX stocks, with Maxim Group repeating the rating for CMRX by listing it as a “Buy.” The predicted price for CMRX in the upcoming period, according to Maxim Group is $20 based on the research report published on April 29th of the current year 2021.
Cowen, on the other hand, stated in their research note that they expect to see CMRX reach a price target of $18, previously predicting the price at $10. The rating they have provided for CMRX stocks is “Outperform” according to the report published on April 23rd, 2021.
Wedbush gave a rating of “Outperform” to CMRX, setting the target price at $21 in the report published on March 31st of the current year.
CMRX Trading at -2.02% from the 50-Day Moving Average
After a stumble in the market that brought CMRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.24% of loss for the given period.
Volatility was left at 5.62%, however, over the last 30 days, the volatility rate increased by 5.36%. Over the last 50 days, in opposition, the stock is trading -2.12% lower at present.
During the last 5 trading sessions, CMRX rose by +7.99%, which changed the moving average for the period of 200-days by +222.63% in comparison to the 20-day moving average, which settled at $7.71. In addition, Chimerix Inc. saw 62.32% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CMRX starting from MIDDLETON FRED A, who purchase 6,950 shares at the price of $7.83 back on Jun 28. After this action, MIDDLETON FRED A now owns 207,523 shares of Chimerix Inc., valued at $54,418 using the latest closing price.
MIDDLETON FRED A, the Director of Chimerix Inc., purchase 3,050 shares at $7.78 during a trade that took place back on Jun 25, which means that MIDDLETON FRED A is holding 200,573 shares at $23,729 based on the most recent closing price.
Stock Fundamentals for CMRX
Current profitability levels for the company are sitting at:
- -828.67 for the present operating margin
The net margin for Chimerix Inc. stands at -810.16. The total capital return value is set at -47.58, while invested capital returns managed to touch -46.71. Equity return is now at value -136.20, with -119.00 for asset returns.
Based on Chimerix Inc. (CMRX), the company’s capital structure generated 3.99 points at debt to equity in total, while total debt to capital is 3.83. Total debt to assets is 3.45, with long-term debt to equity ratio resting at 3.84. Finally, the long-term debt to capital ratio is 3.69.
When we switch over and look at the enterprise to sales, we see a ratio of 41.76, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 5.37 and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.57.